Boehringer Ingelheim announced today a new collaboration with Vanderbilt University, Nashville, Tennessee. The multi-year program complements an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS (Son Of Sevenless). This molecule activates KRAS, a molecular switch that plays a central role in the onset of some of the deadliest cancers.
The collaboration combines pioneering research in the laboratory of Stephen W.
RelSci News & Alerts gets you: